

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6471730

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARC IGLARZ	05/27/2020
RECEIVING PARTY DATA	
Name:	IDORSIA PHARMACEUTICALS LTD
Street Address:	HEGENHEIMERMATTWEG 91
City:	ALLSCHWIL
State/Country:	SWITZERLAND
Postal Code:	4123
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16768604
CORRESPONDENCE DATA	
Fax Number:	(973)912-5236
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	973-912-5232
Email:	file@hoxpat.com
Correspondent Name:	HOXIE & ASSOCIATES LLC
Address Line 1:	75 MAIN STREET
Address Line 2:	SUITE 203
Address Line 4:	MILLBURN, NEW JERSEY 07041
NAME OF SUBMITTER:	MICHAEL J. TSIMARAS
SIGNATURE:	/Michael J. Tsimaras/
DATE SIGNED:	12/29/2020
Total Attachments: 1	
source=IDP-70-US - Assignment - signed - IGLARZ to IDP - confirmatory assignment#page1.tif	

U.S. CONFIRMATORY ASSIGNMENT

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration paid to the undersigned inventor(s) (hereinafter ASSIGNOR) by

[Insert
ASSIGNEE's
Name(s)
Address(es)]

Idorsia Pharmaceuticals Ltd, Heggenheimermattweg 91, 4123 Allschwil, Switzerland
.....
.....
.....

(hereinafter ASSIGNEE), the receipt of which is hereby acknowledged, the undersigned ASSIGNOR hereby acknowledges and confirms that ASSIGNOR has previously assigned and transferred, pursuant to the employment agreement between the ASSIGNOR and ASSIGNEE and laws of Switzerland, unto said ASSIGNEE, its successors, assigns and legal representatives, and to the extent not earlier assigned and transferred under U.S. law hereby assigns and transfers, its entire right, title and interest in and throughout the world, including the United States of America (including its territories and dependencies), the entire and exclusive right, title and interest, including the right to sue for past infringement, if any, and all rights pursuant to 35 U.S.C. §154, to the invention entitled

[Title of
Invention]

**COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2
INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES**

[*If the assignment
is being filed
after the filing of the
application, this
section must be
completed]

for which application for Letters Patent of the United States was executed on even date herewith unless otherwise indicated below:

filed on May 29, 2020, Serial No. 16/768,604

(Bozic & Associates LLC is hereby authorized to insert the series code, serial number and/or filing date herein, when known)


and all Letters Patent of the United States to be obtained therefor on said application or any continuation, division, renewal, substitute, reissue or reexamination thereof, and any other application claiming priority thereto, for the full term or terms for which the same may be granted.

The ASSIGNOR agrees to execute all papers necessary in connection with application and any continuing, divisional, reissue or reexamination applications thereof and also to execute separate assignments in connection with such applications as the ASSIGNEE may deem necessary or expedient.

The ASSIGNOR agrees to execute all papers necessary in connection with any interference, litigation, or other legal proceeding which may be declared concerning this application or any continuation, division, reissue or reexamination thereof or Letters Patent or reissue patent issued thereon and to cooperate with the ASSIGNEE in every way possible in obtaining and producing evidence and proceeding with such interference, litigation, or other legal proceeding.

IN WITNESS WHEREOF, the undersigned inventor(s) has (have) affixed his/her/their signature(s).

[Signature(s)
of Assignor(s)]

..... (SIGNATURE)	<u>Marc BELLET</u> (TYPE NAME) (DATE)
 (SIGNATURE)	<u>Marc IGLARZ</u> (TYPE NAME)	<u>May 29, 2020</u> (DATE)